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ABSTRACT: The objective of this longitudinal study was to estimate the incidence rate
of asthma, and to compare the incidence between subjects with or without baseline
reporting of certain respiratory symptoms.
A follow-up of the random population samples in the European Respiratory Health
Survey (ECRHS) in Sweden, Norway, Denmark, Iceland and Estonia was conducted in
1999–2001, in a population aged 30–54 yrs at follow-up (n=14,731). Asthma was
defined as reporting either asthma or physician-diagnosed asthma, and a reported year
when asthma symptoms were first noticed. Incidence rates, incidence rate ratios and
hazard ratios were calculated with 95% confidence intervals.
The incidence rate of asthma was 2.2 cases per 1,000 person-yrs. The incidence was
higher among females (2.9 cases?1,000 person-yrs-1) than among males (1.5 cases?1,000
person-yrs-1). When subjects with baseline reporting of wheezing were excluded, the
incidence rate decreased to 1.7 cases?1,000 person-yrs-1, with a further decrease to 1.5
cases?1,000 person-yrs-1 after exclusion of subjects with wheezing, nocturnal dyspnoea,
chest tightness and cough. There was a strong association between onset of asthma and
wheezing at baseline.
In this prospective, population-based study, the incidence rate of asthma in the whole
population sample ranged 1.5–2.2?1,000 person-yrs-1, with a higher incidence range
among females. The incidence was dependent on the extent to which subjects with
respiratory symptoms were excluded from follow-up. Hence, for comparability between
studies, the exclusion criteria in the follow-up population must be stated.
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There have been few studies of asthma incidence among
adults. The diagnostic criteria for new-onset asthma have
been based on either clinical investigations, or self-reported
asthma or physician-diagnosed asthma [1, 2]. Reports on
asthma are more common and, over the last 10 yrs,
questionnaire-based incidence studies have been published
in the USA, Scandinavia, Spain and Italy, showing incidence
rates from 1–5 cases per 1,000 person-yrs-1 [3–9].
It is difficult to decide which subjects should be excluded
from the baseline population in a prospective study of asthma
incidence. One key question to consider is: when does a
symptomatic condition present at baseline cross over to be
included in the definition of asthma? More precisely, should
subjects reporting wheezing or other asthma-associated
symptoms (but not asthma) at baseline be considered as a
group with increased risk for asthma onset or should they be
excluded because they probably already have asthma?
The observed incidence rate at follow-up is also dependent
on the extent to which symptomatic subjects are misclassified
as healthy and, hence, are included in the baseline population
[10]. This may be one reason for the varying estimates of
incidence that have been published. One way to decrease this
bias is to widely exclude subjects who report respiratory
symptoms at the start of follow-up.
In a prospective study from Spain, BASAGANA et al. [6]
observed that the incidence rate decreased from 3.3 to
2.8?1,000 patient-yrs when subjects reporting asthma attacks,
use of asthma medications and attacks of nocturnal dyspnoea
at start of follow-up were excluded. The incidence rate further
decreased to 2.0?1,000 patient-yrs when, in addition, subjects
reporting wheezing, nocturnal chest tightness or nocturnal
coughing were also excluded.
Here, a large prospective study of the incidence rate of
asthma among adults from five countries in northern Europe
(Sweden, Denmark, Norway, Iceland and Estonia) is
presented, with the aim of estimating the incidence rate of
adult-onset asthma, and its relation to allergic rhinitis and
respiratory symptoms assessed at the start of follow-up. The
effect on the estimated incidence rate due to different
exclusion criteria at the start of follow-up is also analysed.
Methods
The population of the study were subjects (n=21,802) born
between 1945 and 1973, who participated in stage 1 of the
European Community Respiratory Health Survey (ECRHS
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I), 1989–1992 [11], from: Reykjavik in Iceland; Bergen in
Norway; Umea˚, Uppsala and Go¨teborg in Sweden; Aarhus in
Denmark; and Tartu in Estonia. In 1999–2001, at follow-up,
the eligible subjects were mailed a questionnaire, of which
16,191 (74%) answered.
In the first survey, subjects answered the ECRHS screening
questionnaire, comprising items about wheezing, nocturnal
chest tightness, nocturnal dyspnoea, nocturnal cough, attacks
of asthma during the last 12 months, current use of asthma
medication and allergic rhinitis.
At follow-up the subjects were investigated with another
questionnaire, the first part of which contained questions
identical to those previously used [11]. The second part
included items about self-reported asthma.
Incident asthma was defined as a positive answer to either
"Do you have or have you ever had asthma?" or "Have you
ever had asthma diagnosed by a doctor?", and a reported year
for onset of asthma symptoms [1].
Allergic rhinitis was defined as a positive answer to "Do
you have any nasal allergies including hay fever?".
Never-smoking person-years were defined from the start of
follow-up until the end of the observation period (if the
person did not start to smoke). If the person smoked at the
start of follow-up then smoking person-years were defined
from the start of follow-up until smoke-stop or until the end
of the observation period. If the person started to smoke
during the follow-up period, smoking person-years were
counted from smoke-start until smoke-stop or until the end of
the observation period. Ex-smoking person-years were
counted from the first year after smoke-stop until the year
of follow-up. Smoking history at the end of follow-up was
categorised as never-smoker, ex-smoker, current smoker or
unknown.
Subjects reporting asthma onset before or at the year of
first survey were excluded, as well as subjects reporting
asthma attacks or use of asthma medication at the start of
follow-up, resulting in a study population at risk of 14,731
subjects (tables 1 and 2).
Statistical analyses
Incidence rates were calculated as the number of new cases
of asthma divided by the person-years at risk during the
observation period. When asthma occurred, the subject
ceased to contribute person-years. Incidence rates were
calculated and 95% confidence intervals (CI) have been
outlined assuming a Poisson distribution [12]. Incidence rate
ratios (IRR) were calculated according to Mantel-Haenszel
and odds ratios (OR) were calculated with logistic regression
models. All p-values are two-sided, and they are based on a
Chi-squared test for categorical variables and on a t-test for
continuous variables. The homogeneity between centres
regarding incidence rates of asthma was tested according to
ROTHMAN and GREENLAND [13].
Cox regression analyses were performed with person-years
under observation as the dependent variable and asthma as an
event, stratified for centre. Hazard ratios (HR) are given for
explanatory variables, included simultaneously in the model,
as well as smoking time, sex and age.
Results
With all centres merged, 316 new cases of asthma occurred
during the observation period 1989–2001, based on 141,200
person-years under observation. The cumulative incidence for
the whole period was 2.1%. The crude incidence rate was 2.2
cases?1,000 person-yrs-1 (95% CI 1.8–2.8). The incidence was
higher (pv0.05) among females (2.9 cases?1,000 person-yrs-1)
than among males (1.5 cases?1,000 person-yrs-1). The
incidence was similar among those born in 1960–1973 and
those born in 1945–1959 (2.4 versus 2.1 cases?1,000 person-
yrs-1; pw0.05). The incidence rate during never-smoking time
was 1.8 cases?1,000 person-yrs-1, during ex-smoking time it was
2.1 cases?1,000 person-yrs-1 and during smoking time it was 2.4
cases?1,000 person-yrs-1. IRR (smoking/never-smoking) was
1.3 cases?1,000 person-yrs-1 (95% CI 1.01–1.6) and IRR (ex-
smoking/never-smoking) was 1.2 (95% CI 0.9–1.5). In the
univariate analyses, subjects reporting allergic rhinitis,
respiratory symptoms (nocturnal cough, dyspnoea, or chest
tightness or wheezing) had an increased incidence of asthma
compared with those not reporting the symptoms (table 3).
Table 1. – Prevalence of respiratory symptoms (at baseline) in
a prospective study of 14,731 subjects from northern Europe
Symptom at baseline Responders n Prevalence affirmative
answers %
Wheezing 14586 17.3
Nocturnal chest tightness 12250 7.3
Nocturnal dyspnoea 14653 3.5
Nocturnal cough 14638 25.8
Allergic rhinitis 14566 16.0
All subjects did not answer to all items.
Table 2. – Age, sex, smoking habits and cumulative incidence
of asthma at follow-up in a prospective study of 14,731
subjects from northern Europe
All subjects n 14731
Age mean¡SD 39.8¡7.3
Males 6979 (47.4)
Never smokers 6586 (44.7)
Former smokers 3615 (24.5)
Current smokers 4266 (29.0)
Unknown smoking habits 264 (1.8)
New-onset asthma 316 (2.1)
Data are presented as n (%) unless otherwise stated.
Table 3. – Incident cases of asthma, incidence rates (cases
per 1,000 person-yrs-1 under observation), incidence rate
ratios (IRR) and 95% confidence intervals (CI) in 1989–2001,
in relation to wheezing, nocturnal chest tightness, nocturnal








Yes 112 4.8 2.8 2.3–3.3
No 201 1.7
Nocturnal chest tightness
Yes 49 4.9 2.3 1.8–3.0
No 228 2.1
Nocturnal dyspnoea
Yes 21 4.4 2.1 1.4–3.1
No 292 2.2
Nocturnal cough
Yes 124 3.5 2.0 1.7–2.3
No 187 1.8
Allergic rhinitis
Yes 99 4.9 2.5 2.0–3.0
No 210 1.8
943ASTHMA INCIDENCE IN NORTHERN EUROPE
The highest risk estimate was among those reporting
wheezing at the start of follow-up.
When subjects with respiratory symptoms were step-wise
excluded from the follow-up population, the estimated
incidence decreased from 2.2 to 1.5?1,000 patient-yrs
(table 4). The univariate analyses, with regard to age, sex
and smoking, were also performed after exclusion of subjects
with wheezing, nocturnal dyspnoea, chest tightness and
cough. The incidence was still higher (pv0.05) among females
(1.9 cases?1,000 person-yrs-1) than in males (1.0 cases?1,000
person-yrs-1). The incidence was similar among those born in
1960–1973 and those born in 1945–1959 (1.7 versus 1.3
cases?1,000 person-yrs-1; pw0.05). The incidence rate during
never-smoking time was 1.3 cases?1,000 person-yrs-1, during
ex-smoking time it was 1.8 cases?1,000 person-yrs-1 and
during smoking time it was 1.7 cases?1,000 person-yrs-1. IRR
(smoking/never-smoking) was 1.3 (95% CI 1.03–1.6) and IRR
(ex-smoking/never-smoking) was 1.4 (95% CI 0.97–2.0).
The Cox regression model, with all predictors in the same
model, showed an increased HR for females (HR 1.9, 95% CI
1.5–2.4). Reporting of wheezing and nocturnal cough as well
as allergic rhinitis were associated with an increased risk for
new-onset asthma (table 5). When all subjects reporting
wheezing, nocturnal dyspnoea, chest tightness and cough at
the start of follow-up were excluded, the risk for asthma
among those with allergic rhinitis further increased.
In table 6, the results from different centres are presented.
The highest incidence rate was observed in Iceland (3.6?1,000
patient-yrs-1, 95% CI 3.0–4.9) and the lowest in Estonia
(0.5?1,000 patient-yrs-1, 95% CI 0.2–1.1). The homogeneity
test was not significant (pw0.2, Chi-squared=3.1), meaning
that the test did not detect heterogeneity between centres.
When all subjects reporting wheezing, nocturnal dyspnoea,
chest tightness and cough at the start of follow-up were
excluded, the estimated incidences decreased, but the differ-
ences between centres remained. The fraction of incident cases
with current asthma symptoms (at time of follow-up) was
60% in Iceland and 100% in Estonia. The fraction was 74% in
Aarhus, 71% in Bergen, 79% in Go¨teborg, 84% in Umea˚ and
79% in Uppsala.
Compared with all responders (n=16,191), the nonrespon-
ders (n=5,611) were younger at the start of follow-up (30.8
versus 31.9 yrs, pv0.0001) and had higher prevalence of
wheezing (24.1 versus 21.5%, pv0.0001), nocturnal symptoms
(16.1 versus 13.9%, p=0.0003) and allergic rhinitis (19.8 versus
18.0%, p=0.003). The nonresponders were more often males
(53.4 versus 46.6%, p=0.0004). No significant difference was
found between nonresponders and responders regarding
reported asthma attacks (3.0 versus 2.8%, p=0.40) or use of
asthma medication (3.7 versus 3.5%, p=0.32).
Discussion
The estimated incidence rate of self-reported asthma in this
large prospective study was 2.2 cases?1,000 person-yrs-1
during the period 1989–2001, based on a prospective follow-
up of a population with exclusion of subjects with asthma
Table 4. – Incidence rates of asthma (cases per 1,000 person-years under observation) in 1989–2001 in relation to respiratory
symptoms at start of follow-up




dyspnoea or chest tightness
Wheezing, nocturnal dyspnoea,





Yes 3.5 (2.1–5.5) 2.2 (1.0–4.1)
No 1.7 (1.4–1.9) 1.7 (1.5–2.0)
Nocturnal cough
Yes 2.6 (2.0–3.3) 2.4 (1.8–3.1) 2.3 (1.7–3.1)
No 1.5 (1.3–1.7) 1.5 (1.3–1.7) 1.5 (1.0–2.0)
Allergic rhinitis
Yes 3.8 (2.9–4.8) 3.7 (2.9–4.8) 3.7 (2.8–4.7) 3.4 (2.5–4.7)
No 1.4 (0.95–1.9) 1.3 (0.88–1.8) 1.3 (0.93–1.8) 1.2 (0.94–1.4)
All 1.7 (1.5–2.0) 1.7 (1.5–2.0) 1.6 (1.2–2.2) 1.5 (1.0–2.0)
Data are presented as incident rate ratio (95% confidence interval (CI)).
Table 5. – Hazard ratios (HR) for onset of asthma in 1989–2001 in relation to sex, respiratory symptoms and allergic rhinitis at
start of follow-up
Baseline predictor All subjects Subjects with
wheezing excluded
Subjects with wheezing
or nocturnal dyspnoea excluded
Subjects with wheezing,
nocturnal dyspnoea, chest
tightness and cough excluded
Females 1.9 (1.5–2.4) 1.8 (1.3–2.5) 1.9 (1.4–2.6) 1.8 (1.4–2.6)
Wheezing 2.1 (1.6–2.7)
Nocturnal dyspnoea 1.4 (0.8–2.4) 2.7 (1.4–5.3)
Nocturnal chest tightness 1.3 (0.9–1.9) 1.4 (0.8–2.4) 1.1 (0.6–2.0)
Nocturnal cough 1.4 (1.1–1.8) 1.4 (1.01–1.9) 1.4 (0.99–1.97)
Allergic rhinitis 2.3 (1.8–3.0) 2.7 (2.0–3.6) 3.0 (2.2–4.0) 2.9 (2.1–3.9)
Data are presented as HR (95% confidence interval (CI)). Based on a Cox regression model adjusted for centre, smoking, age and sex, with
simultaneous inclusion of all predictors.
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attacks, use of asthma medications or self-reported asthma at
the start of follow-up. Wheezing and allergic rhinitis were the
factors most strongly associated with a subsequent reporting
of asthma onset. When, in addition, subjects with wheezing,
cough and dyspnoea were excluded, the incidence rate
decreased to 1.5 cases?1,000 person-yrs-1.
The use of self-reported asthma may introduce misclassi-
fication in relation to chronic obstructive pulmonary disease
(COPD). This misclassification is age dependent, because
COPD mainly occurs after 50 yrs of age. In addition, a sex-
dependent misclassification has been described previously
[14]. The age of the population for this study was 30–54 yrs,
which to some extent minimises the misclassification in
relation to COPD. In addition, the incidence rate was not
increased among the oldest part of the population, an
argument against misclassification in relation to COPD.
Self-reported asthma or physician-diagnosed asthma has a
high specificity and a low sensitivity [1, 2]. Regarding asthma,
the gold standard can be a problematic issue, but mostly the
gold standard for asthma has been either clinical investiga-
tions, including metacholine challenge tests or a clinical
investigation performed by a physician. We have recently
validated a sample of subjects responding "yes" and "no" to
the question about physician-diagnosed asthma [15]. Taking
into account the sampling fraction, the specificity of the item
about physician-diagnosed asthma was 0.998 and the
sensitivity was 0.36. Hence, the use of self-reported asthma
in epidemiological studies will cause an underdetection of
subjects with asthma. It is also reasonable to assume that the
false-negatives are subjects with mild asthma, as shown by
our preliminary data (unpublished data). In addition to the
underreporting by the subjects themselves, there is probably
underdiagnosis by the physicians. It has been shown that, in
subjects with mild disease, asthma is often overlooked by
physicians [16].
The reported year of onset for asthma is sensitive to
misclassification, meaning that a subject may report an
incorrect year. We are aware of only one other study
validating the self-reported year of diagnosis or disease
onset among subjects with asthma [15]. In that study, a
telephone interview of 32 subjects with physician-diagnosed
asthma showed that 14 reported the same year (¡1 yr) in the
interview and five subjects (16%) deviated by w5 yrs. The
preliminary data from the present study shows 222 subjects
reporting year of adult-onset asthma 10 yrs after they
received their clinical asthma diagnosis (unpublished data),
with y90% of the subjects reporting correct year of asthma
onset (¡1 yr). In the baseline study (part of ECRHS I),
the screening questionnaire used only measured current
asthma symptoms. Hence, the use of an identical screening
questionnaire at follow-up would not have enabled us to
detect incident cases that occurred and resolved during the
10-yr interval.
In this study, the average response rate was 77%, but in
total only 60% of the original population answered both
questionnaires. This might introduce bias. Nonresponders
were younger males who reported significantly more wheezing
than responders in 1990. However, no difference was found in
the prevalence of asthma and other respiratory symptoms
(other than wheezing) between responders and nonrespon-
ders. The increased prevalence of wheezers among nonre-
sponders may decrease the incidence estimates.
The observed incidence rate, 2.2 cases?1,000 person-yrs-1, is
probably falsely increased because of some misclassification
at baseline, i.e. subjects with asthma but not reporting asthma
may show up during the follow-up as new-onset asthma.
Conversely, the definition of new-onset asthma is based on an
operational definition with low sensitivity, i.e. the observed
incidence is an underestimation of the true underlying process
of asthma onset. The incidence rate of 1.5 cases?1,000 person-
yrs-1, estimated from a baseline population where subjects
reporting different respiratory symptoms have been excluded,
is probably largely free from misclassification at baseline, i.e.
the estimated incidence is at least not too high. In fact, it may
be an underestimation because of the low sensitivity of self-
reported asthma. Hence, the incidence rate for asthma is in
the range 1.5–2.2 cases?1,000 person-yrs-1. This incidence
range is similar to that reported in other studies [5]. However,
some recent longitudinal studies have reported different rates.
RO¨NMARK et al. [4] from Sweden found an incidence rate of 5
cases?1,000 person-yrs-1 among adults; the high incidence may
be caused by the higher ages in the sample, 42–73 yrs. In one
Canadian study [17], a remarkably high incidence was found,
y6 cases?1,000 person-yrs-1 among males and 12 cases?1,000
person-yrs-1 among females, all 25–54 yrs of age. There is no
obvious explanation for these high rates. EAGAN et al. [9],
from the Bergen area in Norway, also noted a higher
incidence of asthma compared with the currrent study, y3.5
cases?1,000 person-yrs-1. In that study, only subjects with
diagnosed asthma at the start of follow-up were excluded. The
incidence rate in the study presented here (with exclusion of
subjects with asthma attacks, use of asthma medications or
self-reported asthma at start of follow-up) from Bergen was
slightly lower, 3.1 cases?1,000 person-yrs-1.
As in most other studies, a higher incidence rate was also
found for females (2.9 cases?1,000 person-yrs-1) compared
with males (1.5 cases?1,000 person-yrs-1). Different factors,
such as airway size, hormonal factor status and socio-
economic factors, have been discussed [18]. The incidence
rate may also reflect a tendency among physicians to diagnose
an asthma-like disorder as asthma in females and COPD in
males [14]. The incidence was independent of age (or birth
year), which is in accordance with most other studies in the
age span 25–50 yrs [5].
In this data set, reporting of allergic rhinitis at the start of
follow-up increased the risk for adult-onset asthma, which is
in accordance with other studies [15, 19–21]. Reporting of
allergic rhinitis may be considered as a proxy for atopy, with
the increased risk only reflecting the influence of atopy.
In this study, an increased risk for asthma during smoking
person-years was observed, as in a previous study [5]. The risk
was rather low, 1.3, which is probably due to bias, because
smokers with respiratory symptoms, such as cough, stop
smoking but receive a diagnosis of asthma a few years later.
The ex-smokers also had a slightly increased incidence rate.
The importance of tobacco smoking for asthma onset among
adults is still controversial. Several studies have found an
increased risk, as summarised by TORE´N and HERMANSSON
[5]. However, several prospective studies have failed to find an
Table 6. – Incidence rates of asthma (cases per 1,000 person-




All subjects Subjects with wheezing,
nocturnal dyspnoea,
chest tightness and cough
at baseline excluded
Aarhus (1991–2001) 1.6 (1.3–2.5) 0.9 (0.43–1.5)
Reykjavik (1989–2001) 3.6 (3.0–4.9) 2.9 (2.0–4.0)
Bergen (1990–1999) 3.1 (2.7–4.2) 2.3 (1.5–3.2)
Go¨teborg (1989–1999) 2.2 (2.1–3.6) 1.1 (0.58–1.8)
Umea˚ (1989–1999) 2.1 (1.8–3.0) 1.0 (0.51–1.6)
Uppsala (1989–1999) 2.1 (1.8–3.1) 1.4 (0.89–2.1)
Tartu (1992–2001) 0.5 (0.2–1.1) 0.3 (0.04–1.2)
Data are presented as incidence rate (95% confidence interval (CI)).
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increased risk for asthma in relation to smoking [3, 6, 22]. To
some extent the negative studies can be explained by the
"healthy smoker effect", which is more manifest if subjects are
only followed for part of their potential smoking time [23].
Negative studies may also be biased, because there is a
tendency to label asthma-like disorders as asthma in non-
smokers but not in smokers [24]. Conversely, active smokers
seem to have more severe asthma than nonsmokers [25]. This
observation is also supported by a case study in which cigarette
smoking is associated with more severe asthma [26]. Hence, the
use of self-reported asthma may overestimate the asthma risk
among smokers, because self-reported asthma probably is
biased in relation to disease severity.
The estimated incidences were different between the
centres. This may be due to a random effect, but, compared
with the other centres, the incidence rate in Iceland was
significantly higher and in Estonia it was significantly lower.
Among the Swedish centres the variability was low, as the
estimated incidence rates were almost identical. Hence, the
difference was more associated with country than with centre.
The prevalence of current asthma symptoms among the
subjects with incident asthma indicated, however, a diagnostic
bias. Iceland, with high incidence, had the lowest prevalence
of current asthma symptoms, indicating that less severe cases
receive a physician9s diagnosis of asthma. However, the
numbers are low, and this may also reflect random effects.
Hence, the present data preclude a definitive answer as to
whether these findings reflect different diagnostic traditions or
a different underlying true rate of disease onset.
In this prospective, population-based study, the incidence
rate of asthma in the whole population ranged 1.5–2.2
cases?1,000 person-yrs-1, with a higher incidence range among
females. The incidence was dependent on the extent to which
subjects with respiratory symptoms were excluded from
follow-up. Hence, for comparability between studies, the
exclusion criteria in the follow-up population must be stated.
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